These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2510294)

  • 1. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
    Roth B; Cerny T; Brunner KW; Küpfer A
    Schweiz Med Wochenschr; 1989 Aug; 119(34):1153-8. PubMed ID: 2510294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of orally administered mesna.
    Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
    Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
    Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
    J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and bioavailability of spectinomycin after i.v., i.m., s.c. and oral administration in broiler chickens.
    Abu-Basha EA; Gehring R; Albwa'neh SJ
    J Vet Pharmacol Ther; 2007 Apr; 30(2):139-44. PubMed ID: 17348899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral bioavailability of mesna tablets.
    Stofer-Vogel B; Cerny T; Borner M; Lauterburg BH
    Cancer Chemother Pharmacol; 1993; 32(1):78-81. PubMed ID: 8462128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
    J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cephalexin in calves after intravenous and subcutaneous administration.
    Garg SK; Chaudhary RK; Srivastava AK
    Acta Vet Hung; 1996; 44(2):195-201. PubMed ID: 8908743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
    Jones MS; Murrell RD; Shaw IC
    Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP; Epelman S; Bush DA
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding.
    Bialer M; Wu WH; Look ZM; Silber BM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1987 Apr; 56(1):21-32. PubMed ID: 3589152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs.
    Benchaoui HA; Cox SR; Schneider RP; Boucher JF; Clemence RG
    J Vet Pharmacol Ther; 2007 Aug; 30(4):336-44. PubMed ID: 17610407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Ormstad K; Orrenius S; Låstbom T; Uehara N; Pohl J; Stekar J; Brock N
    Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.